Long-Term KEYNOTE-426 Data Continue to Support Frontline Pembrolizumab Plus Axitinib as SOC for Advanced ccRCC

The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.

Related Keywords

United States ,Japan ,America ,Briani Rini ,Roche Genentech ,Bristol Myers Squibb ,Hibercell Incyte ,Astrazeneca Medimmune ,Alkermes ,International Metastatic ,Arrowhead Pharmaceuticals ,Pfizer ,Life Sciences ,Genentech ,Debiopharm Group ,Corvus Pharmaceuticals ,Gilead Sciences ,Database Consortium ,Hematology Oncology ,Vanderbilt University Medical Center ,North America ,Western Europe ,Nikang Therapeutics ,Arcus Biosciences ,Dragonfly Therapeutics ,Point Therapeutics ,Surface Oncology ,Asco Annual Meeting ,News ,Conference ,